Esophageal Cancer

From James Van Der Beek spreading awareness about colorectal cancer at a younger age to Gerry Connolly’s recent esophageal cancer diagnosis, here’s what’s happening in the cancer space this week.

For patients with adenocarcinoma of the esophagus and esophagogastric junction, chemoradiotherapy and chemotherapy improved survival versus surgery alone.

I feel most thankful on Father's Day, especially after being told I'd never be able to have children.

Perioperative chemotherapy with chemotherapy led to improved survival outcomes versus neoadjuvant chemoradiation in resectable esophageal cancer.

Research has shown aspirin use to be associated with lower rates of metastasis for some patients.

I've found that nutrition and healthy foods play an important role during cancer.

There is no difference in recovery, complication or cost between the two most common surgical approaches for esophageal cancer.

When I was my husband's caregiver, I tried to make things comfortable, but I'm not sure if the drugs and bedpans could ever make it right.

The GI cancer space has “made huge strides” in recent years, which opened more options for patients with a type of esophageal cancer, an expert said.

The Food and Drug Administration approved Tevimbra for pretreated metastatic or unresectable esophageal squamous cell carcinoma.

This past holiday season made me realize that I feel a strong sense of fulfillment as a cancer survivor and caregiver.

Simultaneous administration of the novel oral S-1 chemotherapy and SIB-RT could improve survival rates for patients aged 70 and older with esophageal squamous cell carcinoma (ESCC).

The hold has been placed due to visual side effects in a number of patients with solid tumors.

Patients who underwent minimally invasive treatment tended to have better quality-of-life outcomes than those who had a full esophagus removal, though there were risk factors for long-term outcomes that should be considered.

NC410 plus Keytruda will be studied in a phase 1b/2 trial for patients with certain solid cancers that either did not respond to or have not been treated with an immunotherapy agent.

I was working hard and feeling burnt out, until a cancer diagnosis forced me to slow down and reevaluate the important things in life.

The manufacturer of one of the cancer treatments announced that it is also participating in clinical trials assessing the safety and efficacy of their product in colorectal and endometrial cancer.

Both Opdivo plus Yervoy and Opdivo plus chemotherapy were approved by the Food and Drug Administration to treat patients with esophageal squamous cell carcinoma.

From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.

The Food and Drug Administration plans on reviewing multiple new cancer therapies this spring.

Keytruda in combination with chemotherapy has just received FDA approval for the treatment of patients with metastatic or locally advanced esophageal and gastroesophageal cancers.

The Food and Drug Administration approved Opdivo for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.

For patients with Barrett’s esophagus, surveillance, drugs and diet can help prevent the development of cancer.

As the range of treatments expands, patients with esophageal cancer can advocate for the care that’s best for them.

The Food and Drug Administration’s approval of Keytruda in recurrent locally advanced or metastatic esophageal squamous cell carcinoma led to new progress for this patient population.